The p53 family of proteins play instrumental roles in mediating the cellular response to stress. The p53-related gene product, p73, occurs as two distinct protein isoforms, referred to as a and b, which dier in the length of the C-terminal region and arise through alternative splicing of the p73 RNA. Here, we describe an analysis of the transcription properties of p73 and show that although there are certain similarities between transcriptional activation mediated by p73 and p53, such as in their sensitivity to adenovirus E1A and the requirement for p300/CBP co-activator proteins, signi®cant dierences are apparent in the response mechanisms. Thus, we ®nd that p73 shows a degree of speci®city for the promoters of target genes that is quantitatively distinct from the response mediated by p53. For example, p73 activates the GADD45 gene more eciently than p53, whereas the reverse situation was apparent for the p21 gene. These eects are, in part, due to the in¯uence of a regulatory domain present in the extended C-terminal of the a isoform. Moreover, we provide evidence that this domain regulates protein abundance by in¯uencing the proteasome-dependent degradation of p73. These data de®ne a novel level of isoform-speci®c control in regulating p73 activity, and thereby highlight a signi®cant dierence between the mechanisms that govern the transcriptional activity of p53 and p73.
Introduction
The gene encoding the p53 tumour suppressor protein is one of the most frequently altered genes in human cancer . In normal cells, wildtype p53 is held in a latent state but, following genotoxic or other forms of stress, post transcriptional mechanisms stabilize p53 to result in an accumulation of p53 protein (Levine, 1997; Giaccia and Kastan, 1998) . The induction of p53 protein leads to either cell cycle arrest or apoptosis Levine, 1997) , eects that contribute to the suppression of malignant disease.
A larger number of studies have correlated tumour suppression by p53 with the ability of p53 to function as a sequence-speci®c transcription factor (Hupp et al., 1992; Crook et al., 1994; Pietenpol et al., 1994) . In this respect, a variety of target genes have been identi®ed that could account for the capacity of p53 to limit proliferation. For example, Waf1/Cip1 encodes the p21 protein, a stoichiometric antagonist of cyclin-dependent kinases (cdks) which, in turn, plays an instrumental role in regulating cell cycle progression (ElDeiry et al., 1993; Harper et al., 1993) . Thus, G1 cdks are in¯uential in regulating the phosphorylation level of the retinoblastoma tumour suppressor protein (pRb) which, in the hypophosphorylated state, interacts with and negatively regulates the activity of the E2F transcription factor to prevent the activation of E2F target genes and hence cell cycle progression (Dulic et al., 1994; Waldman et al., 1995) . Since the activity of p21 is sucient to cause cell cycle arrest (El-Deiry et al., 1993; Harper et al., 1993; Dulic et al., 1994; Waldman et al., 1995) , the induction of transcription of Waf1/Cip1 by p53 is likely to be important in mediating the eects of p53. Moreover, mutations in p53 frequently occur in hot spots that aect the region encoding the DNA binding domain and inactivate its properties as a sequence speci®c transcription factor , supporting the importance of transcriptional control in mediating the physiological consequences of p53 activation.
Another recognized p53 target gene, mdm2, encodes a protein which forms a physical complex with p53 (Momand et al., 1992; Oliner et al., 1993) . MDM2 binds to and incapacitates the tumour suppressor activity of p53 by interacting with and antagonizing the activity of the trans activation domain (Momand et al., 1992; Oliner et al., 1993) . Mice de®cient for mdm2 are not viable unless they also lack the p53 gene (Jones et al., 1995; de Oca Luna et al., 1995) , suggesting that the regulation of p53 is an important physiological function of MDM2. In addition to its ability to act as a cellular antagonist of p53-dependent transcription, MDM2 can promote the degradation of p53, apparently through a ubiquitin-dependent proteasome pathway (Haupt et al., 1997; Kubbutat et al., 1997) . Further, recent studies have suggested that MDM2 can undergo nucleo-cytoplasmic export and that it continuously shuttles between the nucleus and cytoplasm, which may be involved in the ability of MDM2 to function as an oncoprotein (Roth et al., 1998) .
Until recently p53 had been believed to be encoded by a gene that lacked any close relatives. However, this viewpoint has been challenged with the identi®cation of at least two genes which encode proteins that possess a high level of conservation with p53 (Oren, 1997) . The p53 relatives, referred to p73 and p63/Ket1 (Kaghad et al., 1997; Schmale and Bamberger, 1997; Osada et al., 1998; Yang et al., 1998) , display both structural and functional similarities to those of p53.
The p73 encodes at least two distinct polypeptides, referred to as a and b, that arise through alternative splicing of the p73 RNA (Kaghad et al., 1997) . The longer a isoform, possesses an extended C-terminal region of 137 residues although the rest of the protein, with the exception of the last ®ve residues in the b isoform, are shared between the two protein isoforms (Kaghad et al., 1997) . There is signi®cant conservation between p73 and p53, particularly across the DNA binding domain and, importantly, the introduction of p73 into cells can induce the transcription of Waf1/ Cip1 (Kaghad et al., 1997; Jost et al., 1997) , thus suggesting some level of functional overlap between the p73 and p53 response. Consistent with this idea, p73 can halt proliferation and induce apoptosis (Jost et al., 1997; Prabhu et al., 1998) , properties that imply a tumour suppressor-like role. However, although the p73 gene maps to a human chromosomal region that is deleted in a variety of tumours (Kaghad et al., 1997; Nomoto et al., 1998) , a variety of reports have suggested that p73 is not frequently mutated in human tumour cells (Mai et al., 1998; Sunahara et al., 1998; Takahashi et al., 1998) .
Here, we report an analysis of the transcription properties of p73 and, speci®cally, a comparison of the properties of the a and b isoforms on a group of recognized p53-responsive promoters. Our data provide support for the view that the mechanisms through which p53 and p73 activate transcription are similar, since the activation domains of both p53 and p73 require the activity of the p300/CBP co-activator complex (Avantaggiati et al., 1997; Lill et al., 1997; Lee et al., 1998) . It is consistent with this result that p73-dependent transcription is sensitive to the action of the adenovirus E1A protein, which binds to and inactivates p300/CBP proteins (Eckner et al., 1994) . Moreover, the ability of p73 to activate transcription shows a considerable degree of promoter speci®city which, in part, is governed by a C-terminal regulatory domain present in the a-isoform. Furthermore, we provide evidence that this domain has an impact on protein abundance by regulating the proteasome-dependent degradation of p73. These data de®ne a novel level of control in p73-dependent transcription that highlights a major dierence in the regulation of the p73 and p53 response.
Results

Promoter speci®city of p73
The two known isoforms encoded by the p73 gene, a and b, dier in the C-terminal region which is extended by 137 residues in the a isoform (Kaghad et al., 1997) . In addition, there are a number of dierent residues in the shared C-terminal region of each isoform (Kaghad et al., 1997) .
In order to compare the transcription properties of p73 to p53, we related to previous studies that have highlighted the importance of p300/CBP co-activators in regulating the p53 response (Avantaggiati et al., 1997; Lill et al., 1997; Lee et al., 1998) and, to this end, explored the role of p300/CBP in p73-dependent transcriptional activation. Firstly, we employed the adenovirus E1A protein which contains, in the N-terminal region, a domain dedicated to an interaction with p300/CBP coactivator proteins. Thus, we compared the eect of wild-type E1A to E1A D2 ± 36 , which carries a deletion in the region of E1A required for the physical interaction Figure 1 Transcriptional activation by p73 requires p300/CBP proteins. (a) Eect of endogenous p300 on p73 transcriptional activity by adenovirus E1A: the reporter pWWP-luc (1 mg) together with p53 (0.3 mg; tracks 2 ± 4), p73a (0.3 mg; tracks 5 ± 7) or p73b (0.3 mg; tracks 8 ± 10) were transfected with either pCMV-E1A wild-type (3 mg) or pCMV-E1A D2 ± 36 (3 mg) into SAOS2 (p53
) cells. pCMV-bgal (1.5 mg) was included in each transfection as an internal control. Cells were assayed for luciferase and b-galactosidase activity 36*40 h after transfection. The experiments were performed at least three times, and the results shown represent the average from two sets of values. (b) The expression vector encoding pG4 (tracks 2 and 3) or pG4-p300WT (tracks 4 and 5) together with either HA-tagged p73a (tracks 2 and 4) or p73b (tracks 3 and 5) were introduced into SAOS2 cells and after 48 h immunoprecipitation performed with the anti-Gal4 antiserum followed by gel electrophoresis. Immunoblotting was performed with the HA monoclonal antibody 12CA5. Note that the common bands present across tracks 1 ± 5 results from non-speci®c activity with p300/CBP proteins (Eckner et al., 1994) , in SAOS2 cells which are p53 7/7 and express low levels of p73 (data not shown).
Consistent with these results, the ability of p53 to activate transcription of the promoter taken from the p53-regulated gene encoding p21 was compromised by the presence of wild-type E1A, an eect dependent on the integrity of the p300/ CBP binding domain since E1A D2 ± 36 failed to inactivate p53-dependent transcription (Figure 1 , compare tracks 3 and 4). A similar analysis performed on p73a and b-dependent transcription also supported a role for p300/CBP in transcriptional activation as again wild-type E1A, but not E1A D2 ± 36 , caused a reduction in p73-dependent transcription (Figure 1a , compare tracks 6 and 7
Figure 2 Domains in p300 and p73. (a) Diagrammatic representation of the functional region of p300 is shown in upper side. The three cysteine/histidine-rich domain (CH1, CH2 and CH3) are indicated as shaded boxes. The two-hybrid assay was performed in SAOS2 cells where the Gal4 reporter pG5E1b-luciferase was introduced together with expression vectors encoding the indicated Gal4-p300 hybrids (1 mg) with (+) or without (7) p73b-VP16 (5 mg). pCMV-bgal (1.5 mg) was included in each transfection as an internal control. The results shown represent the average from three sets of values. (b) Two-hybrid assays to de®ne the p73 domain sucient for p300 binding: the indicated p73-VP16 expression vectors (5 mg) were introduced into SAOS2 cells together with pG4-p300 611 ± 2284 (1 mg) and the pG5E1b-luciferase (1 mg). The data presented are the averages from three sets of values normalized to the activity of the internal control pCMV-bgal with 9 and 10). These results therefore suggest a role for p300/CBP co-activator proteins in p73-dependent transcription.
To gain further evidence for p300/CBP proteins in regulating p73 activity, we determined if the two isoforms of p73 could form a physical complex with Figure 3 Target gene speci®city of p73. (a) The p53 reporters pWWP-luc, pGADD45-luc or pMDM2-luc (1.5 mg) together with expression vectors for p53 (0.5 mg), p73a (0.5 mg) or p73b (0.5 mg) were transfected into SAOS-2 cells as indicated. The data presented re¯ect the average from three sets of values normalized to the b-galactosidase activity from the internal control. (b) Immunoblotting analysis of endogenous p21, GADD45, MDM2 and c-Myc polypeptides in transiently transfected cells. SAOS2 and U2OS cells were transfected with expression vectors for p53, p73a or p73b as indicated, and subjected to immunoblotting with the anti-p21, anti-GADD45, anti-MDM2 or anti-c-Myc antibodies. In tracks 1 and 5,`7' indicates an empty vector (pCMV-HA). The polypeptides are indicated on the right p300 in mammalian cells using both immunochemical and two-hybrid based approaches. Co-transfection into SAOS2 cells of expression vectors encoding Gal4-p300WT together with either p73a or b tagged with the HA epitiope, followed by immunoprecipitation with anti-Gal4 and immunoblotting with anti-HA, con®rmed that the interaction can occur in mammalian cells since the p73a and b polypeptides were clearly present in the p300 immunoprecipitate but not the control treatment (Figure 1b , compare tracks 2 and 3 with 4 and 5). Combined with the previous data, these results indicate that the process of transcriptional activation mediated by p73 involves p300/CBP coactivator proteins.
We gained additional evidence for an association between p73 and p300 in a mammalian two-hybrid assay in which p300, expressed as a hybrid protein fused to the Gal4 DNA binding domain, was coexpressed with p73b fused to the VP16 activation domain, and the response of a Gal4 transcriptional reporter monitored. Only when pG4-p300 611 ± 2284 and p73b-VP16 were co-expressed was an induction of reporter gene activity apparent ( Figure 2a , compare tracks 1, 2, 3 and 4), a result consistent with an interaction between the two-hybrid proteins. To de®ne the region in p300 required for the interaction with p73, we used the two-hybrid system and assessed the interaction between hybrid proteins in which dierent regions of p300 were fused to the Gal4 DNA binding domain. The interaction domain in p300 for p73b mapped to a C-terminal region encompassed within residue 1572 to 1903, as G4-p300 1572 ± 1903 eciently activated the Gal4 reporter when p73b-VP16 was coexpressed ( Figure 2a , compare tracks 11 and 12). In this respect, the interaction domain in p300 for p73 has a location similar to that previously assigned to p53, namely with a region in p300 that includes the CH3 domain (Avantaggiati et al., 1997; Lee et al., 1998) .
A similar approach was taken to identify the domain in p73 that is responsible for the interaction with p300. Thus, dierent regions of p73 were constructed as hybrid proteins with VP16 and co-expressed with G4-p300 611 ± 2284 . The interaction domain mapped to the shared N-terminal region in the two p73 isoforms, encompassed within residue 1 to 54, as when p73 1 ± 54 -VP16 was co-expressed with G4-p300 611 ± 2284 an induction of activity from the reporter construct was apparent (Figure 2b , compare tracks 2 and 5). This result is compatible with the signi®cant homology between p73 and p53 that exists in the N-terminal region which, in p53, harbours the trans activation domain. Overall, these results identify p300 as a coactivator used by p73 in transcriptional activation and, furthermore, de®ne the N-terminal region of p73 as mediating the interaction between p73 and the CH3 domain of p300.
Promoter speci®c eects of p73 on p53-responsive genes
Having established a role for p300/CBP co-activators in p73-dependent transcription, it was of interest to investigate the promoter speci®city of p73. For this, we compared the transcription properties of p73a and b with those of p53 on a panel of known p53-responsive promoters, taken from the genes encoding p21, GADD45 and MDM2 .
As expected, the expression of exogenous p53 in SAOS2 cells resulted in a marked induction of transcription from each promoter construct ( Figure  3a , tracks 2, 6 and 10). Similarly, both isoforms of p73 could activate each of the promoters studied (Figure 3a, tracks 3, 4, 7, 8, 11 and 12) . However, notable dierences in the level of transcriptional activation were apparent when the eects of p53, p73a and p73b were compared. Thus, the activation of the p21 promoter (in pWWP-luc) and the MDM2 promoter was most eciently mediated by p53 ( Figure  3a , tracks 2 and 10). Remarkably, however, clear dierences were apparent in the eect of p73 isoforms, which was particularly apparent on the GADD45 promoter where p73b caused a much greater level of activation than either p73a or p53 (Figure 3a , compare tracks 6, 7 and 8). Moreover, a similar eect was seen on the MDM2 promoter where p73b activated more eciently than p73a (Figure 3a , compare tracks 11 and 12) but, in contrast, the p21 promoter was activated with about equal eciency by each isoform (Figure 3a , compare tracks 3 and 4). These results reveal a striking promoter selectivity in the eects of p53 and p73 and, for p73, strongly suggest that the a and b isoforms dier considerably in their ability to regulate the transcriptional response of target promoters.
However, it was important to establish whether the eects observed on the transfected promoter constructs were relevant to the transcriptional control of endogenous genes. To pursue this question, we as indicated. Extracts from transfected cells were immunoblotted with anti-HA antibody. (b) After stripping, the same membrane was re-immunoblotted with anti-c-Myc monoclonal antibody measured p21, GADD45 and MDM2 protein levels in SAOS2 and U2OS cells after transfection with expression vectors encoding p53 and p73. As a control, we measured the levels of endogenous cMyc, whose gene is not known to be directly regulated by p53. Although there were marginal dierences in the levels of induction seen between the two cell lines, we found in general that there was a good correlation between the eects on transfected promoters and endogenous protein levels. Thus, p53 induced p21 protein expression more eciently than p73, although both p73 isoforms were nevertheless capable of augmenting p21 levels in both cell types (Figure 3bi , tracks 1 ± 8). For GADD45 in SAOS2 cells, both p53 and p73a caused an induction of protein although a more dramatic eect was apparent with p73b ( Figure 3bii, tracks 1 ± 4) . In U2OS cells, again the b isoform induced GADD45 levels more eciently than p73a although, in contrast to SAOS2 cells, p73a failed to induce levels above the control treatment ( Figure 3bii , tracks 5 ± 8). Similarly, p73b was much more ecient at inducing MDM2 levels than p73a and, whilst p53 induced MDM2 in both cell types, the eect was considerably less than that observed with p73b ( Figure 3biii , tracks 1 ± 8). As an internal control, we measured the levels of endogenous c-Myc where, in contrast to the eects on p21, GADD45 and MDM2, we failed to detect any dierences in the levels in cells expressing exogenous p53 or p73. The analysis of the eects of p53 and p73 on p53-responsive promoters therefore correlates signi®cantly with and re¯ects the response of endogenous genes. Importantly, these data provide evidence for the selective response of promoters to p53 and p73 and, in addition, identify clear functional dierences in the eects of the p73a and b isoform on the activity of target genes. Overall, the b-isoform was more ecient at inducing activity compared to the a isoform on GADD45 and MDM2.
The C-terminal region governs the abundance and in¯uences the transcriptional activity of p73
It was possible that the dierence in eects observed in the transcriptional response relate to the protein levels of the a and b isoforms. To investigate this idea, we measured the levels of the a and b isoforms after transfection into SAOS2 cells. Under these conditions, it was clear that the b isoform was present at considerably greater levels than the a isoform ( Figure  4a , compare tracks 1, 2 and 3), thus suggesting that the C-terminal domain in a can in¯uence the level of p73 protein.
To strengthen this idea, we constructed a mutant derived from the a isoform that lacks the C-terminal region from residues 459, p73a 1 ± 458 , and compared the levels of p73a 1 ± 458 to wild-type p73a after introduction into SAOS2 cells. As a control for loading eciency, we measured the level of endogenous c-Myc by reimmunoblotting the same membrane. Under these conditions, we found that the level of p73a 1 ± 458 was much greater than the level of the wild-type p73a isoform (Figure 4b , compare tracks 3 and 4). Furthermore, the level of c-Myc was comparable in the dierent cell extracts (Figure 4b , compare tracks 1, 2, 3 and 4), con®rming and extending the earlier results suggesting that the C-terminal region of p73 regulates protein abundance.
It was of interest, given the earlier results on the transcription properties of p73a and b, to compare the functional eects of p73a to p73a 1 ± 458 . When the response of the p21, GADD45 and MDM2 promoters was assessed, the eect of p73a 1 ± 458 mirrored the behaviour of p73b documented earlier. Speci®cally, the p21 promoter (in pWWP-luc) showed a marginal, but signi®cant, increase in activity by p73a 1 ± 458 in comparison to wild-type p73a (Figure 5a , tracks 1, 2 and 3). In contrast, there was a much greater induction of both the GADD45 and MDM2 promoters by p73a 1 ± 458 relative to wild-type p73a (Figure 5b and c, Figure 5 Response of p73 target genes (a), (b) and (c). The reporter pWWP-luc (a), pGADD45-luc (b) or pMDM2-luc (c) together with expression vectors for wild-type p73a (0.1 mg) or p73a 1 ± 458 (0.1 mg) were transfected into SAOS2 cells as indicated. The values shown represent the average from three sets of values and are the relative level of luciferase to b-galactosidase activity from the internal control tracks 4 ± 6). These data con®rm that the in¯uence of the C-terminal region in p73 on protein levels impacts directly on the transcriptional activity of responsive promoters.
It was possible that the C-terminal region of p73 could in¯uence protein abundance through altering the half-life of p73. We assessed this possibility by introducing expression vectors for p73a and b into SAOS2 cells and following their protein levels after pulse-chase' and immunoprecipitation. An analysis of protein levels until 4 h post-pulse treatment indicated that the b isoform was considerably more stable than the a isoform. After 2 h, the level of p73b was about 50% greater than p73a (Figure 6 , track 5), suggesting that the C-terminal region in the a isoform in¯uences the half-life of the p73 protein.
Modulation of p73 levels via a proteasome-dependent pathway
The results presented thus far on the role of the Cterminal region in regulating the abundance of p73 prompted us to assess whether a proteasome-dependent pathway of protein degradation may be involved. We tested this idea using the proteasome antagonist Nacetyl-leucinyl-norleucinyl (LLNL), which prevents the proteasome-dependent degradation of ubiquitinated substrates (Homan et al., 1996) .
In order to assess the eect of LLNL on p73 abundance, we introduced expression vectors for either p73a, p73b or p73 1 ± 458 into U2OS cells and thereafter examined p73 levels in the transfected cells. Compared to the control treatment, the presence of LLNL caused a marked induction in the level of p73a (Figure 7a and b, compare track 2) . In contrast, we failed to observe a similar induction of p73b upon treatment with LLNL where, in contrast, a marginal reduction in p73b level was apparent (Figure 7a and b, compare track 3). In cells expressing p73a 1 ± 458 there was no apparent change in protein level upon treatment with LLNL (Figure 7a and b, compare track 4). Overall, therefore, these results support the contention that the C-terminal extension in the a isoform regulates protein stability through a pathway that is sensitive to LLNL, suggesting that the process is mediated by a ubiquitin-dependent proteasome pathway.
Moreover, if this mechanism were to be physiologically relevant, then we would expect an induction of endogenous p73 upon treatment with LLNL. We assessed this possibility in U2OS cells in which a p73-related polypeptide possessing a molecular weight of that expected for p73a is the predominant isoform expressed (Figure 7c, track 1) . We found that treatment of U2OS cells with LLNL caused an induction in the protein level of p73 (Figure 7c , compare tracks 1, 2, 3 and 4), a result that concurs with the data derived from studying the eect of LLNL on exogenous p73 (Figure 7a  and b) . Thus, we conclude that the regulation of endogenous p73 involves a ubiquitin-dependent proteasome pathway. S methionine and thereafter chased for the indicated times as described in Materials and methods. The levels of p73a and p73b were resolved by immunoprecipitation with the HA antibody, and are indicated on the right Figure 7 The C-terminal region of p73 in¯uences protein level through a proteasome-dependent degradation pathway. (a) and (b) U2OS cells were transfected with either empty vector (pCMV-HA), HA-tagged p73a, p73b or p73a 1 ± 458 as indicated. Extracts were prepared and immunoblotted with anti-Ha antibody (upper panel) and, after stripping the membrane, re-immunoblotted with anti-cMyc monoclonal antibody (lower panel). In (b), 30 n post-transfection cells were treated with 10 mM LLNL for a further 6 h before being harvested and analysed as described above. (c) U2OS cells were treated with LLNL as indicated for 6 h and thereafter extracts prepared for immunoblotting with an anti-p73 antibody. Track 1 shows the molecular weight markers and a polypeptide corresponding to the molecular weight of p73a is indicated
Regulation of p21 in p53
7/7 cells
The treatment of cells with low levels of actinomycin D (1 nM) activates the p53 response (Kaghad et al., 1997) . It was therefore of considerable interest to examine the response of p53 target genes in SAOS2 cells and thereafter assess the role of p73 which, the earlier results show, can induce in SAOS2 cells the expression p53-responsive genes. By immunoblotting, 1 nM actinomycin D caused an increase in p21 levels ( Figure 8a , compare tracks 1 and 2), a result consistent with activation being mediated through an endogenous p53-related protein.
To further characterize the response to actinomycin D, we ®rstly established the importance of the p300 co-activator which, as shown earlier (Figures 1 and 2) , plays an important role in enabling p73 to activate transcription. For this analysis, we used a version of p300, p300 1572 ± 2283 , which behaves in a dominantnegative fashion on p53 (Lee et al., 1998) and contains the p73 interaction domain (Figure 2 ). The introduction of p300 1572 ± 2283 into SAOS2 cells caused a signi®cant reduction in the induction of p21 by actinomycin D (Figure 6b , compare tracks 2 and 3), thus suggesting a role for p300 in regulating the induction of p21 and, because p300 1572 ± 2283 contains the interaction domain for p73 and p53, by implication these results support the idea that the response is mediated by a p53-related protein. Consistent with this view, the N-terminal region of p73, p73 1 ± 135 , when expressed in SAOS2 cells also reduced the induction of p21 by actinomycin D (Figure 8b , compare tracks 2 and 4). Overall, these data are consistent with a role for a member of the p53 family of proteins (other than p53) in inducing p21 in response to actinomycin D in SAOS2 cells.
Discussion
Transcriptional activation by p73 requires p300/CBP co-activators It is known that p73 and p53 share a high level of conservation, particularly across their DNA binding domains (Kaghad et al., 1997) . In contrast, the conservation in the N-terminal trans activation domains is less apparent although the overall acidic nature is shared with p53 (Kaghad et al., 1997) . The data presented here establish that p73-dependent transcription requires a contribution from the p300/ CBP family of proteins and, in this respect, it is known that p300/CBP proteins function as transcriptional co-activators for a wide variety of dierent transcription factors, although within p300/CBP dedicated interaction domains exist for dierent transcription factors (Shikama et al., 1997) . Our results de®ne the interaction domain for p73 as residing in a similar location as that previously ascribed to p53, namely in the CH3 region (Avantaggiati et al., 1997; Lee et al., 1998) . Thus, although the activation domains of p73 and p53 are the least conserved domains between the two proteins, the mechanism of transcriptional activation does, nevertheless, involve common mechanism.
It is also noteworthy that p73, like p53, is sensitive to the eects of the adenovirus E1A protein. It is known that E1A possesses an N-terminal domain that is responsible for binding, and incapacitating, the coactivator properties of p300/CBP proteins (Eckner et al., 1994) . In this respect, the E1A binding domain in p300/CBP maps to a similar location as that required for an interaction with p53 and p73 (Avantaggiati et al., 1997; Lee et al., 1998) , suggesting that competition between E1A and p53 for p300/CBP may play a role in mediating the eects of E1A. However, it has been reported that other viral oncoproteins, such as adenovirus E1B, SV40 large T antigen and HPV E6 fail to interact with p73, in contrast to their eects on p53 (Marin et al., 1998) . Despite this ability to discriminate between p73 and p53, our study suggests that other viral oncoproteins, such as E1A, will nevertheless compromise aspects of the p73 response through controlling p300/CBP. 1572 ± 2283 or p73 1 ± 135 expression vector. After 18 h posttransfection, cells were treated with 1 nM actinomycin D for a further 24 h incubation, and cell extracts were prepared. Endogenous p21 or c-Myc levels were analysed by immunoblotting with either anti-p21 or anti-c-Myc antibody as described. Track 1 shows untransfected SAOS2 cells
Promoter speci®city of p73 proteins
The conservation between p53 and p73 implied that there may be an overlap in the transcriptional response of target genes and, consistent with this prediction, it is known that p73 can cause the activation of the p53 target gene p21 (Kaghad et al., 1997; Jost et al., 1997) . Our data con®rm this observation, and extend the analysis to two additional target genes, namely those encoding GADD45 and MDM2. However, although each gene could respond to p53 and p73, there was a striking dierence in the quantitative level of response. For example, GADD45 was very inducible by p73b, but less so by p53 and p73a, whereas MDM2 was activated more by p53 and p73, and eciently by b compared to the a isoform. These results argue that p53 and p73 can activate a common set of responsive genes and therefore establish that there is likely to be considerable overlap in the p53 and p73 response pathways. Very importantly, they document for the ®rst time the dierential response of target genes to p53 and the two known isoforms of p73. Given that the p73 isoforms arise through alternative splicing (Kaghad et al., 1997) , the data de®ne this is a level of control that has a signi®cant impact on the functional properties of p73. Physiologically, it is likely that cells expressing the b rather than a isoform may facilitate a more favourable p73 response.
Of course, the ability of the p73 isoforms to form heteromers with either each other or p53 is likely to be an important parameter that impacts on the response of target genes. However, since the composition of p53/p73 complexes in physiological conditions has yet to be resolved, it is not clear how complex formation between dierent p53 family members would in¯uence the results presented here. In this respect, the induction of p21 by actinomycin D in SAOS2 cells, and the block to induction caused by introducing dominant-negative versions of p300 or p73, are consistent with a role for a p53 family member, such as p73, in the stress response.
A regulatory domain in the C-terminal region of p73
Our studies on the p73 isoforms indicated, under the same expression conditions, that the b isoform reached greater levels than the a isoform. The most straight-forward interpretation of these data is that the C-terminal domain in p73a modulates protein stability, a view consistent with the properties of p73a 1 ± 548 , which was also present at increased levels. An analysis of their half-life indicated that subtle dierences were apparent between the two isoforms, and subsequent experiments established that the level of p73a could be augmented by treating cells with an antagonist of proteasome-dependent degradation. These results suggest that the C-terminal region of p73, the presence of which is regulated by alternative splicing of the p73 RNA, harbours a domain dedicated to controlling the level of p73 protein and that part of the mechanism involved in mediating these eects is likely to involve a ubiquitin-dependent proteasome pathway.
In turn, this analysis of the functional domains in p73 highlights a similarity and dierence in the processes that control the activity p53 family proteins. For p53, a domain present in the C-terminal region which functions to negatively-regulate the p53 response is modulated by a variety of signals (Giaccia and Kastan, 1998) . The properties of p73 argue strongly for a C-terminal domain that, in an analogous fashion to the role of the domain in p53, functions to negatively regulate the p73 response, thus de®ning a level of similarity between the p53 and p73 response. In contrast, the regulation of this domain through alternative splicing of RNA appears to be a novel aspect of p73 control. We do not know whether there are other mechanisms, apart from alternative splicing of the p73 RNA, that can modulate the Cterminal domain. However, it is possible that in cells expressing the a isoform that the activity of p73 is under the control of diverse signals in a similar fashion to the regulation of p53 activity.
It is of considerable interest that the increased levels of p73b correlate with the enhanced transcriptional eect of b relative to a on certain responsive promoters, a similar eect being apparent when the p73 mutant, p73a 1 ± 458 , was assessed. However, the same eect was not apparent on all responsive promoters. For example, although the activity of the p21 promoter was increased by both p73b and p73a 1 ± 458 , this eect was quite marginal when compared to the response of the GADD45 and MDM2 promoters. One potential implication of these results is therefore that an increased p73b level will not necessarily correlate with a proportional increase in the activity of all target promoters, suggesting that the eects of the C-terminal domain are, in fact, somewhat promoter selective.
Regulation of the p73 response
The p53 family of proteins is regarded widely as playing critical roles in the cellular response to stress. Our study shows that in comparison to p53, the p73 family member exhibits considerable dierences in its transcriptional properties and that p73 is likely to be subject to a fundamentally distinct level of control mediated through isoform-speci®c regulation. Thus, although p53 and p73 overlap in the spectrum of transcriptionally responsive target genes, there appear to be dierences in the mechanisms that control dierent family members.
Materials and methods
Plasmids and transient transfection
For transfection into SAOS2 cells, cells were incubated in 10% serum throughout and transfected with either pWWPluc (El-Deiry et al., 1993) , pGADD45-luc (Chen et al., 1996) or pMDM2-luc (Friedlander et al., 1996) with either the expression vector for p53 (Lee et al., 1998) or p73a and p73b (Kaghad et al., 1997) and harvested 40 ± 46 h post-transfection. For the mammalian two-hybrid assay, 1 mg of pG4, pG4-p300 611 ± 2284 , -p300 611 ± 1257 , -p300 1302 ± 1572 , -p300 1572 ± 2284 or -p300 1572 ± 1903 (Lee et al., 1998) were transfected with either p73a-VP16, p73b-VP16, p73 1 ± 54 -VP16, p73 1 ± 132 -VP16 or p73 182 ± 490 -VP16. All transfections were performed using the calcium phosphate procedure and incubated an internal control pCMV-bgal.
The p73-VP16 constructs were prepared by subcloning the dierent parts of p73 into the expression vector containing the VP16 activation domain of pCMV-VP16 (Lee et al., 1998) . p73a 1 ± 458 was generated by internal deletion. The Gal4 reporter G5E1b-luciferase has been described previously (Lee et al., 1998) . p73a and p73b, pCMV-E1A and pCMV-E1A D2 ± 36 , and pG4-p300WT were a gift from D Caput (Kaghad et al., 1997) , JR Nevins (Kraus et al., 1992) and A Giordano (Yuan et al., 1996) respectively.
Gene reporter assays
For luciferase assay, cell extracts were prepared in reporter lysis buer (25 mM Tris-H 3 PO 4 pH 7.8, 2 mM 1,2-diaminocyclohexane tetra acetic acid, 2 mM DTT, 10% glycerol and 1% Triton X-100). After removing cell debris, extracts were assayed for luciferase activity by mixing 300 ml luciferase reagent (Promega) with 60 ml cell extracts and measuring the activity with a luminometer (Berthold lumat). b-galactosidase assays were performed as described previously (Sambrook et al., 1989) .
Immunoprecipitation and immunoblotting
After 48 h, SAOS2 cells were washed twice in PBS and harvested by scraping into cold TNN buer (50 mM Tris-HCl pH 7.4, 250 mM NaCl, 5 mM EDTA, 0.5% NP-40, 50 mM NaF, 1 mM DTT, 1 mM PMSF, 0.2 mM sodium orthovanadate, leupeptin (0.5 mg/ml), protease inhibitor (0.5 mg/ml), trypsin inhibitor (1.0 mg/ml), aprotinin (0.5 mg/ml) and bestatin (40 mg/ml)) and incubated on ice for 30 min. The cell extract was centrifuged for 10 min at 12 000 g and precleared by incubating with protein-G agarose for 1 h at 48C with constant rotation. The supernatant was harvested and anti-mouse Gal4 monoclonal antibody (RK5C1, Santa Cruz) added for 1 h at 48C. Protein-A agarose (50% v/v, Boehringer Mannheim) was added and the incubation continued for another 1 h at 48C. The agarose beads were collected by centrifugation for 30 s at 5000 g, the supernatant was removed and the pellet was washed three times in TNN.
Immunoblotting was subsequently performed with antimouse HA1 (12CA5, Boehringer Mannheim).
To measure the level of p53 family-inducible gene products, SAOS2 and U2OS cells were transfected with p53, p73a or p73b expression vector. Cell extracts were prepared in TNN as described above. Immunoblotting was performed with either anti-rabbit p21 (C-19, Santa Cruz), anti-rabbit GADD45 (H-165, Santa Cruz), anti-mouse MDM2 (Ab-1, Calbiochem) or anti-mouse c-Myc (9E10, Santa Cruz) antibody.
To compare the stability of p73a, p73b and p73a 1 ± 458 , transfected SAOS2 cells were lysed in buer A (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 1 mM PMSF, leupeptin (10 mg/ml), pepstatin (10 mg/ml), aprotinin (10 mg/ml) and trypsin inhibitor (10 mg/ml) and precleared by centrifugation. The pellet was resuspended and lysed with TNN, and cell debris were removed by centrifugation. Immunoblotting was performed with either anti-mouse HA antibody or anti-mouse c-Myc antibody.
Metabolic in vivo labelling
To assess the stability of p73a and p73b, 16 h after transfection the medium was changed and, after a further 8 h, replaced with methionine-free DMEM containing 5% dialysed foetal bovine serum. Cells were metabolically labelled with 35 S methionine for 1 h, washed three times, and chased for 0, 0.5, 1.0, 2.0 or 4.0 h in normal medium. Cell were harvested in TNN buer and immunoprecipitated with the HA monoclonal antibody.
Proteasome antagonist treatment
Transfected and nontransfected U2OS cells were exposed for 6 h to the proteasome antagonist N-CBZ-Leu-Leu-Leu-AL (LLNL, Sigma) in DMEM and 10% FBS. Cells were lysed in buer A (10 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, 1 mM PMSF, leupeptin (10 mg/ml), pepstatin (10 mg/ml), aprotinin (10 mg/ml) and trypsin inhibitor (10 mg/ml) and precleared by centrifugation. The pellet was resuspended and lysed with TNN, and cell debris removed by centrifugation. Immunoblotting was performed with either anti-mouse HA, anti-mouse c-Myc or anti-goat p73 (C-20, Santa Cruz) antibody. Once the immunoblot was exposed it was incubated with a stripping buer (2% SDS, 62.5 mM Tris-HCl pH 6.8, 100 mM b-mercaptoethanol) and re-immunoblotted.
